Compare · DARE vs JNJ
DARE vs JNJ
Side-by-side comparison of Dare Bioscience Inc. (DARE) and Johnson & Johnson (JNJ): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DARE and JNJ operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- JNJ is the larger of the two at $574.10B, about 19162.8x DARE ($30.0M).
- Over the past year, DARE is down 37.4% and JNJ is up 54.6% - JNJ leads by 92.0 points.
- JNJ has been more active in the news (11 items in the past 4 weeks vs 6 for DARE).
- JNJ has more recent analyst coverage (25 ratings vs 1 for DARE).
- Company
- Dare Bioscience Inc.
- Johnson & Johnson
- Price
- $2.00+0.25%
- $240.03+0.63%
- Market cap
- $30.0M
- $574.10B
- 1M return
- -23.81%
- +6.99%
- 1Y return
- -37.40%
- +54.63%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2014
- News (4w)
- 6
- 11
- Recent ratings
- 1
- 25
Dare Bioscience Inc.
Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, focuses on developing and marketing products for women's health in the United States. The company develops therapies in the areas of contraception, fertility, and sexual and vaginal health. Its products in advanced clinical development include DARE-BV1, a bioadhesive hydrogel formulated with clindamycin phosphate 2% to treat bacterial vaginosis in a single administration that has completed Phase 3 clinical trials; Ovaprene, a hormone-free monthly vaginal contraceptive; and Sildenafil Cream, a cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder. The company's Phase 1-ready products are DARE-HRT1, a combination of bio-identical estradiol and progesterone intravaginal ring for the treatment of vasomotor symptoms in hormone therapy; DARE-VVA1, a vaginally delivered formulation of tamoxifen to treat vulvar vaginal atrophy in patients with hormone-receptor positive breast cancer; and DARE-FRT1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth and broader luteal phase support as part of an in vitro fertilization treatment plan. Its products in pre-clinical stage include DARE-LARC1, a combination product designed to provide reversible contraception; ORB-204 and ORB-214, an injectable formulations of etonogestrel to provide contraception over 6-month and 12-month periods; and DARE-RH1, a non-hormonal contraception for men and women. The company is headquartered in San Diego, California.
Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Latest DARE
- Daré Bioscience Announces the Upcoming Launch of Flora Sync LF5™ Vaginal Probiotic Capsules
- SEC Form DEFA14A filed by Dare Bioscience Inc.
- SEC Form DEFA14A filed by Dare Bioscience Inc.
- Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-HPV, its Novel Investigational Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer
- Dare Bioscience Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities
- Daré Bioscience Initiates Phase 2 Study of DARE-HPV, a Novel Pharmacologic Treatment for Persistent High-Risk HPV Infection with No FDA-Approved Therapies
- SEC Form 10-Q filed by Dare Bioscience Inc.
- Dare Bioscience Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Daré Bioscience Reports First Quarter 2026 Financial Results and Provides Business Update
- Positive Interim Phase 3 Results Highlight Potential of Ovaprene®, Novel Hormone-Free Contraceptive
Latest JNJ
- Johnson & Johnson Expands U.S. Availability of TECNIS PureSee IOL, an Advanced Lens Option for Cataract Surgeons and Patients
- IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven disease with no FDA-approved therapies
- Johnson & Johnson Hit with $32 Million Verdict in Los Angeles Asbestos Trial
- Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform
- Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease
- Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm
- RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer
- New TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma
- FDA approves label expansion, cementing TREMFYA® as the only IL‑23 inhibitor proven to help stop further joint damage
- Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results